SF

SFA Therapeutics

YC S21

Philadelphia, US · Founded 2016 · 4 employees · 3 known investors

sfatherapeutics.com ↗

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

Founders & leadership· Y Combinator alumni (S21)

Ira SpectorinFounder

Alla ArzumanyaninCo-Founder & Chief Development Officer

Mark Feitelsonin𝕏Co-Founder & Scientific Advisor

IC

Ira C. SpectorCo-Founder & Chief Scientific Officer

Investors · 3

Y

Y CombinatorMountain View · $500K – $500K

AC

Acequia CapitalreportedSeattle

BE

Ben Franklin Technology PartnersreportedPennsylvania